| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
|
Proc Natl Acad Sci U S A
|
2004
|
2.58
|
|
2
|
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
|
Blood
|
2002
|
2.25
|
|
3
|
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2007
|
1.99
|
|
4
|
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
|
Proc Natl Acad Sci U S A
|
2010
|
1.84
|
|
5
|
Immunohistochemical detection of WT1 protein in a variety of cancer cells.
|
Mod Pathol
|
2006
|
1.62
|
|
6
|
High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.
|
Clin Cancer Res
|
2002
|
1.49
|
|
7
|
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study.
|
Leuk Res
|
2012
|
1.42
|
|
8
|
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.
|
Int J Cancer
|
2002
|
1.32
|
|
9
|
AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
|
Blood
|
2005
|
1.26
|
|
10
|
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
|
Int J Hematol
|
2003
|
1.18
|
|
11
|
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
|
J Neurosurg
|
2008
|
1.16
|
|
12
|
Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma.
|
Cancer Sci
|
2003
|
1.15
|
|
13
|
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
|
Blood
|
2005
|
1.10
|
|
14
|
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
|
Cancer Immunol Immunother
|
2002
|
1.08
|
|
15
|
Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle.
|
Int J Oncol
|
2009
|
1.08
|
|
16
|
WT1 peptide vaccine for the treatment of cancer.
|
Curr Opin Immunol
|
2008
|
1.04
|
|
17
|
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.
|
Int J Oncol
|
2008
|
1.04
|
|
18
|
Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors.
|
Cancer Sci
|
2004
|
1.02
|
|
19
|
Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
|
Br J Haematol
|
2002
|
1.02
|
|
20
|
Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group.
|
Pathol Res Pract
|
2010
|
1.01
|
|
21
|
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma.
|
Cancer Sci
|
2004
|
1.01
|
|
22
|
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies.
|
Blood
|
2002
|
0.98
|
|
23
|
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
|
Jpn J Clin Oncol
|
2006
|
0.98
|
|
24
|
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
|
Cancer Immunol Immunother
|
2011
|
0.96
|
|
25
|
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
|
Cancer Sci
|
2003
|
0.96
|
|
26
|
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.
|
Int J Cancer
|
2009
|
0.95
|
|
27
|
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
|
J Immunother
|
2014
|
0.95
|
|
28
|
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
|
Microbiol Immunol
|
2007
|
0.95
|
|
29
|
CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.
|
Neuro Oncol
|
2011
|
0.94
|
|
30
|
Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas.
|
Cancer Sci
|
2003
|
0.94
|
|
31
|
Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.
|
Cancer Res
|
2010
|
0.92
|
|
32
|
WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
|
ScientificWorldJournal
|
2007
|
0.91
|
|
33
|
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.
|
Cancer Sci
|
2006
|
0.91
|
|
34
|
Epstein-barr virus in diffuse large B-Cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries.
|
J Med Virol
|
2011
|
0.91
|
|
35
|
Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
|
J Clin Oncol
|
2005
|
0.90
|
|
36
|
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
|
Microbiol Immunol
|
2004
|
0.90
|
|
37
|
CD48 as a novel molecular target for antibody therapy in multiple myeloma.
|
Br J Haematol
|
2011
|
0.89
|
|
38
|
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
|
Int J Hematol
|
2007
|
0.89
|
|
39
|
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
|
Anticancer Res
|
2009
|
0.88
|
|
40
|
Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
|
J Neurosurg
|
2012
|
0.88
|
|
41
|
Prognostic significance of Wilms tumor gene (WT1) mRNA expression in soft tissue sarcoma.
|
Cancer
|
2006
|
0.88
|
|
42
|
Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
|
Ann Hematol
|
2007
|
0.86
|
|
43
|
High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.
|
Cancer Sci
|
2009
|
0.86
|
|
44
|
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
|
J Immunother
|
2007
|
0.85
|
|
45
|
Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
|
Cancer Sci
|
2009
|
0.84
|
|
46
|
Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma.
|
Cancer Sci
|
2003
|
0.84
|
|
47
|
Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.
|
Anticancer Res
|
2004
|
0.84
|
|
48
|
Presence of B-cell clones in T-cell lymphoma.
|
Eur J Haematol
|
2011
|
0.84
|
|
49
|
Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
|
Jpn J Clin Oncol
|
2010
|
0.84
|
|
50
|
WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
|
Eur J Haematol
|
2010
|
0.84
|
|
51
|
The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
|
Transpl Immunol
|
2003
|
0.83
|
|
52
|
WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
|
Anticancer Res
|
2012
|
0.83
|
|
53
|
Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
|
Anticancer Res
|
2012
|
0.83
|
|
54
|
Low Wilms' tumor gene expression in tumor tissues predicts poor prognosis in patients with non-small-cell lung cancer.
|
Cancer Invest
|
2011
|
0.83
|
|
55
|
WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
|
Rinsho Ketsueki
|
2009
|
0.82
|
|
56
|
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.
|
Int J Hematol
|
2003
|
0.82
|
|
57
|
Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
|
Clin Cancer Res
|
2002
|
0.82
|
|
58
|
Diffuse large B-cell lymphoma in the young in Japan: a study by the Osaka Lymphoma Study Group.
|
Am J Hematol
|
2007
|
0.82
|
|
59
|
HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria.
|
Blood
|
2002
|
0.82
|
|
60
|
The Wilms' tumor gene WT1 is a common marker of progenitor cells in fetal liver.
|
Biochem Biophys Res Commun
|
2005
|
0.81
|
|
61
|
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
|
Int J Hematol
|
2007
|
0.81
|
|
62
|
Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
|
Vaccine
|
2011
|
0.81
|
|
63
|
Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation.
|
Transplantation
|
2004
|
0.81
|
|
64
|
Immunohistochemical detection of WT1 protein in endometrial cancer.
|
Anticancer Res
|
2009
|
0.81
|
|
65
|
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
|
Cancer Immunol Immunother
|
2004
|
0.81
|
|
66
|
Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group.
|
Case Rep Oncol
|
2009
|
0.81
|
|
67
|
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.
|
J Cancer Res Clin Oncol
|
2012
|
0.81
|
|
68
|
WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
|
Pediatr Hematol Oncol
|
2009
|
0.81
|
|
69
|
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
|
Cancer Immunol Immunother
|
2015
|
0.80
|
|
70
|
WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.
|
Int J Med Sci
|
2010
|
0.80
|
|
71
|
"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further development.
|
Curr Med Chem
|
2008
|
0.80
|
|
72
|
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
|
Anticancer Res
|
2011
|
0.80
|
|
73
|
WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
|
Cell Physiol Biochem
|
2015
|
0.80
|
|
74
|
Frequency of intravascular large B-cell lymphoma in Japan: study of the Osaka Lymphoma Study Group.
|
J Hematol Oncol
|
2011
|
0.80
|
|
75
|
WT1 peptide immunotherapy for cancer in children and young adults.
|
Pediatr Blood Cancer
|
2010
|
0.80
|
|
76
|
Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.
|
Histopathology
|
2012
|
0.80
|
|
77
|
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
|
Microbiol Immunol
|
2008
|
0.80
|
|
78
|
A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
|
Microbiol Immunol
|
2008
|
0.79
|
|
79
|
Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
|
Leuk Res
|
2010
|
0.79
|
|
80
|
WT1 expression correlates with angiogenesis in endometrial cancer tissue.
|
Anticancer Res
|
2010
|
0.79
|
|
81
|
Polymorphous lymphoproliferative disorder: a clinicopathological analysis.
|
Virchows Arch
|
2010
|
0.78
|
|
82
|
Vaccination with WT-1 (Wilms' tumor gene-1) peptide and BCG-CWS in melanoma.
|
Eur J Dermatol
|
2012
|
0.78
|
|
83
|
Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients.
|
Brain Tumor Pathol
|
2010
|
0.78
|
|
84
|
WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.
|
Immunotherapy
|
2010
|
0.78
|
|
85
|
Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide.
|
Cancer Sci
|
2010
|
0.78
|
|
86
|
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
|
Anticancer Agents Med Chem
|
2009
|
0.77
|
|
87
|
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
88
|
Wilm's tumor gene WT1 peptide immunotherapy for pulmonary metastasis from adenoid cystic carcinoma of the salivary gland.
|
Oral Oncol
|
2010
|
0.77
|
|
89
|
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
|
Anticancer Res
|
2010
|
0.77
|
|
90
|
Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
|
Virchows Arch
|
2009
|
0.77
|
|
91
|
Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
|
Cancer Med
|
2014
|
0.77
|
|
92
|
The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients.
|
Leuk Lymphoma
|
2008
|
0.77
|
|
93
|
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
|
Int J Hematol
|
2003
|
0.77
|
|
94
|
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
|
J Immunother
|
2013
|
0.77
|
|
95
|
Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen.
|
Haematologica
|
2003
|
0.77
|
|
96
|
[Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
|
Brain Nerve
|
2009
|
0.76
|
|
97
|
Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.
|
Anticancer Res
|
2014
|
0.76
|
|
98
|
Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
|
Anticancer Res
|
2012
|
0.76
|
|
99
|
[Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
|
Rinsho Ketsueki
|
2005
|
0.76
|
|
100
|
Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
|
Cancer Immunol Immunother
|
2015
|
0.76
|
|
101
|
Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.
|
Cancer Sci
|
2012
|
0.76
|
|
102
|
Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer.
|
Jpn J Clin Oncol
|
2004
|
0.76
|
|
103
|
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
|
Transplantation
|
2002
|
0.76
|
|
104
|
Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.
|
Expert Rev Hematol
|
2014
|
0.76
|
|
105
|
Differential radiation sensitivity to morphological, functional and molecular changes of human thyroid tissues and bone marrow cells maintained in SCID mice.
|
Mutat Res
|
2008
|
0.75
|
|
106
|
[Cancer immunotherapy targeting WT1 product which overexpressess in various kinds of malignant neoplasms].
|
Tanpakushitsu Kakusan Koso
|
2003
|
0.75
|
|
107
|
[III. Peptide vaccination therapy against brain tumors].
|
Gan To Kagaku Ryoho
|
2015
|
0.75
|
|
108
|
Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
|
Oncol Res Treat
|
2017
|
0.75
|
|
109
|
Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
|
Anticancer Res
|
2011
|
0.75
|
|
110
|
[Cellular and humoral immune responses against WT1 products overexpressed in hematopoietic malignancies].
|
Rinsho Ketsueki
|
2002
|
0.75
|
|
111
|
An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
|
J Immunother
|
2016
|
0.75
|
|
112
|
Functional human Th17 clones with WT1-specific helper activity.
|
Cancer Immunol Immunother
|
2012
|
0.75
|
|
113
|
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.
|
Int J Hematol
|
2005
|
0.75
|
|
114
|
[Identification of myeloma-initiating cells and development of their targeting therapy].
|
Rinsho Ketsueki
|
2013
|
0.75
|
|
115
|
Tumor immunology. Editorial overview.
|
Curr Opin Immunol
|
2008
|
0.75
|
|
116
|
[WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
|
Rinsho Ketsueki
|
2011
|
0.75
|
|
117
|
Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect.
|
Int Immunopharmacol
|
2007
|
0.75
|